Resumen
Treatment of magnolol represents a new therapeutic strategy that may reduce the risk of vascular diseases associated with abnormal vascular smooth muscle cell (VSMC) migration or thrombin/protease-activated receptor 1 (PAR-1) activation.
Palabras claves